MTCO2P34

Across TCGA pan-cancer cohorts, MTCO2P34 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTCO2P34 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTCO2P34 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCO2P34 expression acts as an unfavorable survival marker.

MESO, OV, and STAD are the cancer types where MTCO2P34 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.077	0.580	<.001	126	view →
OV	OS	Tertile	III,IV	0.434	0.689	<.001	72	view →
STAD	DFS	Tertile	II,III,IV	0.297	0.630	<.001	57	view →
BRCA	OS	Tertile	All	0.215	0.581	.009	24	view →
KIRC	DFS	Tertile	IV	0.221	0.603	.046	18	view →
SKCM	OS	Tertile	II,III,IV	0.587	0.842	.025	12	view →
BLCA	DFS	Tertile	III,IV	0.159	0.572	.036	9	view →
LGG	DFS	Tertile	All	0.355	0.757	.022	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTCO2P34–MESO (OS)

Open the MESO breakdown →